EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN OBESE PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: ARISTOPHANES SUBGROUP ANALYSIS — Steven Deitelzweig (2019) | RDL Network
EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN OBESE PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: ARISTOPHANES SUBGROUP ANALYSIS
Wallis C. Y. Lau, Carmen Olga Torre, Kenneth K. C. Man, Henry Morgan Stewart, Sarah Seager, Mui Van Zandt, Christian Reich, Jing Li, Jack Brewster, Professor Gregory Lip, Aroon D. Hingorani, Li Wei, Ian Chi Kei Wong
Xiaoyan Li, Steve Deitelzweig, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Professor Gregory Lip
Wallis C. Y. Lau, Ching‐Lung Cheung, Kenneth K. C. Man, Esther W. Chan, Chor‐Wing Sing, Professor Gregory Lip, Chung‐Wah Siu, Joanne K.Y. Lam, Alan C.H. Lee, Ian Chi Kei Wong
Discussion(0)
No comments yet. Be the first to comment.